Rewriting the human genome
Take a deep dive into the fast-growing market of CRISPR, the gene editing tool that won the 2020 Nobel Prize in Chemistry
Add bookmark
According to recent estimates, 7.9 million children are born each year with birth defects of genetic or partially genetic origins. Additionally, more than 10 per cent of adults worldwide suffer from genetic disorders.
Debilitating and deadly diseases like cancer are on the rise. Additionally, 31 percent of the global population is food insecure leading to lack of consistent nourishment and stunted growth, illness, and premature death.
Clustered regularly interspaced short palindromic repeats (CRISPR) has the potential to solve some of the world’s biggest issues including rare diseases, genetic mutations and food insecurity. This is because CRISPR enables scientists to rewrite the genetic code in almost any organism, while being cheaper, simpler and more precise than any of its gene-editing predecessors.
This whitepaper by PatSnap provides an in-depth look into the history, trends, challenges and research shaping the future of CRISPR-Cas9 technology, a two-component system used for effective targeted gene editing.
Download this white paper to find out about:
• The history of CRISPR and its market context
• The evolving business, science and IP ecosystem of CRISPR
• The successes and failures of this technology, from solving blood disorders to growing genetically modified crops
